TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8174727

Group type: EXPERIMENTAL
Intervention: Cryopreserved oocytes
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control oocytes
Number of subjects: 254
Study: 2966017

Group type: EXPERIMENTAL
Intervention: t‐PA 25 mg and UK 0.5 million U (group I)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: t‐PA 25 mg and UK 1.0 million U (group II)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: t‐PA 1.0 mg/kg and UK 0.5 million U (group III)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: t‐PA 1.0 mg/kg and UK 1.0 million U (group IV)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: t‐PA 1.0 mg/kg and UK 2.0 million U (group V)
Number of subjects: 146

Group type: COMPARATOR
Intervention: t‐PA alone (previous study)
Number of subjects: 146
Study: 29430801

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg combined with insulin
Number of subjects: 445

Group type: COMPARATOR
Intervention: Insulin (glargine or lispro)
Number of subjects: 445
Study: 27741182

Group type: EXPERIMENTAL
Intervention: 24-hour interval administration of mifepristone and misoprostol
Number of subjects: 509

Group type: COMPARATOR
Intervention: Simultaneous administration of mifepristone and misoprostol
Number of subjects: 509
Study: 25133876

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (ICS) for 8 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IL-25 measurements
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Plasma IL-25 levels
Number of subjects: 43
Study: 22627969

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Surgery (GSV stripping)
Number of subjects: 430
Study: 20194129

Group type: EXPERIMENTAL
Intervention: 20% of maximum effort for 2 seconds
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20% of maximum effort for 4 seconds
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40% of maximum effort for 2 seconds
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40% of maximum effort for 4 seconds
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5% of maximum effort for 1 second
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 50% of maximum effort for 1 second
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5% of maximum effort for 5 seconds
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 50% of maximum effort for 5 seconds
Number of subjects: 9
Study: 18581184

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) dye
Number of subjects: 159

Group type: COMPARATOR
Intervention: Lymphazurin blue (LB) dye
Number of subjects: 159
Study: 16051646

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11836010

Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU, intranasally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8573621

Group type: COMPARATOR
Intervention: AdCFTR (2 x 10^5 to 2 x 10^8.5 plaque forming units) administered to the nasal epithelium of one nostril
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control nostril (untreated)
Number of subjects: 9
Study: 2596317

Group type: EXPERIMENTAL
Intervention: Acetazolamide 20 mg/kg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31504868

Group type: EXPERIMENTAL
Intervention: Increasing maintenance methadone dose by 30%
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Adding oxycodone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Adding a single dose of gabapentin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control condition (usual OAT dose)
Number of subjects: 17
Study: 31389824

Group type: EXPERIMENTAL
Intervention: Radial artery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right internal thoracic artery (RITA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral internal thoracic artery (BITA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saphenous vein grafts (SVG)
Number of subjects: 0
Study: 27849406

Group type: EXPERIMENTAL
Intervention: Microneedle fractional radiofrequency system (MFRS) - deep dermal layer
Number of subjects: 13

Group type: COMPARATOR
Intervention: Microneedle fractional radiofrequency system (MFRS) - superficial dermal layer
Number of subjects: 13
Study: 26086157

Group type: EXPERIMENTAL
Intervention: Retrocolic gastroenteric reconstruction
Number of subjects: 73

Group type: COMPARATOR
Intervention: Antecolic gastroenteric reconstruction
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (DGE)
Number of subjects: 73
Study: 24803841

Group type: EXPERIMENTAL
Intervention: DDDR plus Atrial Preference Pacing (APP) algorithm (APP ON group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional dual-chamber pacing mode (DDDR group)
Number of subjects: 60
Study: 21756523

Group type: EXPERIMENTAL
Intervention: IV methylprednisolone (MP) followed by oral MP (125 mg bolus, followed by 40 mg 6 hourly and then oral MP 0.6 mg/kg/day for 2 weeks)
Number of subjects: 97

Group type: COMPARATOR
Intervention: IV hydrocortisone (HC) followed by oral prednisolone (200 mg 6 hourly until discharge, followed by prednisolone 0.75 mg/kg/day for 2 weeks)
Number of subjects: 97
Study: 19888784

Group type: EXPERIMENTAL
Intervention: ALO-01 whole (60 mg capsules)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALO-01 crushed (60 mg capsules)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine sulfate solution (MSS) (120 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17222897

Group type: EXPERIMENTAL
Intervention: Cross-modal related probes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Speech-only related probes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrelated probes
Number of subjects: 0
Study: 15495903

Group type: EXPERIMENTAL
Intervention: Syllables with only one cue to stress (spectral tilt)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Syllables with multiple cues to stress
Number of subjects: 2

Group type: COMPARATOR
Intervention: Syllables marked only by spectral tilt
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Stress cues usage
Number of subjects: 2
Study: 11485129

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual medical care (Control)
Number of subjects: 0
Study: 9590315

Group type: EXPERIMENTAL
Intervention: TPN-glucose (75% glucose)
Number of subjects: 16

Group type: COMPARATOR
Intervention: TPN-lipid (15% glucose)
Number of subjects: 16
Study: 8163252

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg once daily at bedtime
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062
Study: 2754562

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 29
Study: 773507

Group type: EXPERIMENTAL
Intervention: Oxygen administered by MC mask throughout the first 24 hours in hospital
Number of subjects: 157

Group type: COMPARATOR
Intervention: Air administered by MC mask throughout the first 24 hours in hospital
Number of subjects: 157
Study: 31389889

Group type: EXPERIMENTAL
Intervention: Robotic-assisted TKA
Number of subjects: 1406

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 1406
Study: 31087021

Group type: EXPERIMENTAL
Intervention: EHR configuration limiting to 1 patient record open at a time (restricted; n = 1669)
Number of subjects: 3356

Group type: COMPARATOR
Intervention: EHR configuration allowing up to 4 records open concurrently (unrestricted; n = 1687)
Number of subjects: 3356
Study: 27753127

Group type: EXPERIMENTAL
Intervention: Two brief obesity prevention interventions
Number of subjects: 261

Group type: COMPARATOR
Intervention: Educational video control
Number of subjects: 261
Study: 26258318

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 178

Group type: COMPARATOR
Intervention: Daptomycin
Number of subjects: 178
Study: 23758068

Group type: EXPERIMENTAL
Intervention: Education in critical thinking using simulated scenarios and reflective journaling
Number of subjects: 0

Group type: COMPARATOR
Intervention: No education in critical thinking (Control group)
Number of subjects: 0
Study: 23270443

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Antioxidant preparation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 19279969

Group type: EXPERIMENTAL
Intervention: Group 1: resin based sealant Ultraseal XT (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 2: adhesive system Scotchbond Multi Purpose Plus used as a sealant (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 3: primer (SBMP) and Ultraseal XT (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 4: primer, bond (SBMP) and Ultraseal XT (n=10)
Number of subjects: 40
Study: 17597043

Group type: EXPERIMENTAL
Intervention: Skeletonized ITA
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pedicled ITA
Number of subjects: 84
Study: 14757900

Group type: EXPERIMENTAL
Intervention: Interdisciplinary rehabilitation program (7 weeks duration, including pain school, cognitive behavioral therapy, gradual withdrawal of pain-relieving drugs)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Interdisciplinary rehabilitation program (7 weeks duration)
Number of subjects: 158
Study: 11895205

Group type: EXPERIMENTAL
Intervention: I-125 (144 Gy, TG-43)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Pd-103 (125 Gy, NIST-99)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Comparison of I-125 and Pd-103
Number of subjects: 110
Study: 11579696

Group type: EXPERIMENTAL
Intervention: Artificially carbonated bath (36 degrees C, CO2 300 ppm, 20 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Freshwater bath (36 degrees C, 20 minutes)
Number of subjects: 0
Study: 7515773

Group type: EXPERIMENTAL
Intervention: sulfo‐mucopolysaccharides (SMPS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 2687336

Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 971966

Group type: EXPERIMENTAL
Intervention: Home care as part of treatment
Number of subjects: 583

Group type: COMPARATOR
Intervention: Control group (hospital treatment)
Number of subjects: 583
Study: 31580707

Group type: EXPERIMENTAL
Intervention: Intraoperative laser acupuncture on PC6 and LI4 acupoints combined with metoclopramide prophylaxis
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group receiving only metoclopramide prophylaxis
Number of subjects: 88
Study: 30335629

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27815645

Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment (PRT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 24
Study: 25138765

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (500 mg on day 1 and then 250 mg/day for 5 days)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Oral doxycycline (200 mg/day for 1 month)
Number of subjects: 110
Study: 23161899

Group type: EXPERIMENTAL
Intervention: GLPG0259 (50 mg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21807834

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (CBT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 101
Study: 19357529

Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Number of subjects: 300

Group type: COMPARATOR
Intervention: SBR
Number of subjects: 300
Study: 17019283

Group type: EXPERIMENTAL
Intervention: Computer-based ergonomics training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 45
Study: 14579085

Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 21
Study: 10684841

Group type: EXPERIMENTAL
Intervention: Topical nipradilol (0.25%)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Topical timolol (0.5%)
Number of subjects: 47
Study: 9344406

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with tacrine (80 mg/day, 120 mg/day, or 160 mg/day)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Tacrine (80 mg/day, 120 mg/day, or 160 mg/day) without ERT
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 8457044

Group type: EXPERIMENTAL
Intervention: Pulse oximetry monitoring
Number of subjects: 20802

Group type: COMPARATOR
Intervention: Control (no pulse oximetry monitoring)
Number of subjects: 20802
Study: 2943811

Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant hepatitis B vaccine
Number of subjects: 302

Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Both vaccines (plasma-derived and recombinant)
Number of subjects: 302
Study: 31971071

Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Conventional Physical Training (CPT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of VRT and CPT (COMB)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (VRT and CPT)
Number of subjects: 45
Study: 29846887

Group type: EXPERIMENTAL
Intervention: BI 425809 10, 25, 50 or 75 mg once daily or 75 mg twice daily (young subjects); 25 mg or 50 mg once daily (elderly subjects)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 26713415

Group type: EXPERIMENTAL
Intervention: Brace treatment for patellofemoral OA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraarticular steroids
Number of subjects: 0
Study: 25176136

Group type: EXPERIMENTAL
Intervention: Ivabradine (up to 10 mg twice daily)
Number of subjects: 19102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19102

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 19102
Study: 22715869

Group type: EXPERIMENTAL
Intervention: Video instruction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-on-one instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: No education (control)
Number of subjects: 0
Study: 20633151

Group type: EXPERIMENTAL
Intervention: Implantable two‐channel peroneal nerve stimulator
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional walking device (ankle‐foot orthosis, orthopedic shoes, or no device)
Number of subjects: 29
Study: 18328198

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 44
Study: 16219926

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 885

Group type: COMPARATOR
Intervention: Standard-dose chemotherapy
Number of subjects: 885
Study: 12475163

Group type: EXPERIMENTAL
Intervention: Stabilization appliance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control appliance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mixed treatment (control appliance followed by stabilization appliance)
Number of subjects: 60
Study: 9477929

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 8573809

Group type: EXPERIMENTAL
Intervention: Leukocyte depletion with LG-6 arterial line filter after aortic declamp (Group F, n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No leukocyte depletion (Group C, n = 14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Leukocyte depletion (Group F)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No leukocyte depletion (Group C)
Number of subjects: 28
Study: 2085585

Group type: EXPERIMENTAL
Intervention: Curled Tenckhoff catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional straight type catheter
Number of subjects: 0
Study: 479385

Group type: EXPERIMENTAL
Intervention: 60 mg nefopam hydrochloride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 120 mg nefopam hydrochloride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 650 mg aspirin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30929028

Group type: EXPERIMENTAL
Intervention: Acupressure bands plus relaxation MP3 and written handout (expectancy-enhancing)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Acupressure bands plus relaxation MP3 and written handout (expectancy-neutral)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group without bands or MP3 (standard care)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Intervention patients receiving doxorubicin
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Intervention patients with high pre‐treatment anxiety
Number of subjects: 242
Study: 28127827

Group type: EXPERIMENTAL
Intervention: Pragmatic treatment of the lumbar spine and prescriptive treatment of bilateral hips (LBP + HIP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pragmatic treatment of the lumbar spine only (LBP)
Number of subjects: 84
Study: 25830267

Group type: EXPERIMENTAL
Intervention: Arthroscopic shoulder capsular release and manipulation, followed by a stretching program (twice daily for at least 15 minutes for 3 months)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Home therapy program consisting of terminal range of motion low-grade stretches (twice daily for at least 15 minutes for 3 months)
Number of subjects: 26
Study: 23489186

Group type: EXPERIMENTAL
Intervention: Post-operative intervention (successful tumor removal)
Number of subjects: 18
Study: 21339317

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Optimal pharmacological treatment (OPT)
Number of subjects: 60
Study: 19794937

Group type: EXPERIMENTAL
Intervention: Meditoxin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Botox
Number of subjects: 60
Study: 15990691

Group type: EXPERIMENTAL
Intervention: Rapid IPC
Number of subjects: 104

Group type: COMPARATOR
Intervention: Slow IPC
Number of subjects: 104
Study: 12456542

Group type: EXPERIMENTAL
Intervention: Webster‐Stratton 10 week parenting programme delivered by trained health visitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Webster‐Stratton 10 week parenting programme
Number of subjects: 0
Study: 10356602

Group type: EXPERIMENTAL
Intervention: Anticoagulants (specific type not mentioned)
Number of subjects: 130

Group type: COMPARATOR
Intervention: No therapy (Control group)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 1500 mg daily
Number of subjects: 130
Study: 7854076

Group type: EXPERIMENTAL
Intervention: Completion of a 10-page booklet containing a personal standardized medical record
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no personal record completion)
Number of subjects: 200
Study: 1826454

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a (rIFN alpha 2a) administered alone (273 men)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Recombinant interferon‐alpha 2a (rIFN alpha 2a) combined with vinblastine (91 men)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a (rIFN alpha 2a) with escalating doses (3, 9, and 18 million I.U. daily for 3 days, then 36 million I.U. daily)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a (rIFN alpha 2a) at a dose of 36 million I.U. daily for approximately 10 weeks followed by maintenance schedule
Number of subjects: 364
Study: 6818164

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 36
Study: 30727989

Group type: EXPERIMENTAL
Intervention: Teacher-delivered intervention to promote autonomous motivation toward physical activity
Number of subjects: 502

Group type: COMPARATOR
Intervention: Waitlist control intervention (alternative training on monitoring physical functional capacity in children with special needs)
Number of subjects: 502
Study: 29191160

Group type: EXPERIMENTAL
Intervention: McGrath MAC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Airway scope
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study: 26471194

Group type: EXPERIMENTAL
Intervention: ChiRunning (trainer-led)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (combined active and educational)
Number of subjects: 22
Study: 25123061

Group type: EXPERIMENTAL
Intervention: DHA-rich intervention supplement capsules consumed over the course of pregnancy
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: Gestational age at delivery
Number of subjects: 1571

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: Other clinical or lifestyle factors explored
Number of subjects: 1571
Study: 22901032

Group type: EXPERIMENTAL
Intervention: Sleep-wake group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wake-sleep group
Number of subjects: 70
Study: 19243711

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine extended-release 15 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine extended-release 30 mg
Number of subjects: 16
Study: 17233432

Group type: EXPERIMENTAL
Intervention: Quality of life assessment methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent qualified papers on health outcomes
Number of subjects: 0
Study: 15764049

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1% plus clindamycin topical solution 1%
Number of subjects: 300

Group type: COMPARATOR
Intervention: Clindamycin topical solution 1% alone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1% alone
Number of subjects: 300
Study: 12522973

Group type: EXPERIMENTAL
Intervention: Physical exercise program (60% to 80% of heart rate reserve, 3 sessions per week for 60 minutes each for 8 months)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63